Moleculin Biotech’s (NASDAQ:MBRX) lock-up period will end on Tuesday, November 29th. Moleculin Biotech had issued 1,540,026 shares in its public offering on June 2nd. The total size of the offering was $9,240,156 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Shares of Moleculin Biotech (NASDAQ:MBRX) opened at 3.00 on Tuesday. Moleculin Biotech has a 1-year low of $2.34 and a 1-year high of $9.58. The company’s market capitalization is $33.76 million. The company’s 50 day moving average is $3.53 and its 200-day moving average is $5.69.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates, many of which are based on license agreements. The Company’s lead drug candidate is liposomal Annamycin (Annamycin). The Company has two other drug development projects in progress, one involving a portfolio of small molecules, known as the WP1066 Portfolio, and the other is WP1122 Portfolio.

5 Day Chart for NASDAQ:MBRX

Receive News & Stock Ratings for Moleculin Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc and related stocks with our FREE daily email newsletter.